Comparative in vitro activities of GAR-936 against aerobic and anaerobic animal and human bite wound pathogens.
about
Tigecycline: a review of a new glycylcycline antibioticUpdate on the taxonomy and clinical aspects of the genus fusobacterium.Activity and diffusion of tigecycline (GAR-936) in experimental enterococcal endocarditisIn vitro antimicrobial susceptibility of Brachyspira pilosicoli isolates from humans.Treatment of bacterial skin and skin structure infections.Oritavancin and tigecycline: investigational antimicrobials for multidrug-resistant bacteria.Tigecycline: an evidence-based review of its antibacterial activity and effectiveness in complicated skin and soft tissue and intraabdominal infections.Moxifloxacin in the treatment of skin and skin structure infections.Tigecycline: a new glycylcycline for treatment of serious infections.Tigecycline: a novel glycylcycline antibiotic.Treatment options for multidrug-resistant bacteria.Investigational treatments for postoperative surgical site infections.Antimicrobial prophylaxis in colorectal surgery: focus on ertapenem.Animal bite-associated infections: microbiology and treatment.Comparative in vitro susceptibilities of 396 unusual anaerobic strains to tigecycline and eight other antimicrobial agents.Comparison of the in vitro activity of the glycylcycline tigecycline (formerly GAR-936) with those of tetracycline, minocycline, and doxycycline against isolates of nontuberculous mycobacteria.Activities of the glycylcycline tigecycline (GAR-936) against 1,924 recent European clinical bacterial isolates.In vitro activities of tigecycline (GAR-936) and 12 other antimicrobial agents against 90 Eikenella corrodens clinical isolates.Pharmacodynamics of moxifloxacin against anaerobes studied in an in vitro pharmacokinetic model.Activity of Tigecycline against Coryneform Bacteria of Clinical Interest and Listeria monocytogenes.Comparative in vitro antimicrobial activity of tigecycline, a new glycylcycline compound, in freshly prepared medium and quality controlIn vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infections.
P2860
Q28278979-B01DE6E2-68B8-42F1-881E-B352B8648352Q30712612-C8AC5624-2B4D-4FAD-8DB2-6EF7CD0029CEQ34720793-2F0ED57D-7583-4F4A-9542-E3B216041062Q35103199-EA3CE0B0-8BA8-487D-AD16-1AC22F6083FDQ35183731-445339F9-BC7B-4B46-9579-DE11325D1753Q35637071-BF83F79C-EE9C-4FE7-85E3-D9725E707D9CQ35876393-68668B9B-01F9-4E79-A029-DF8A76251612Q35919259-D320EC6D-9F8A-4E46-A7A2-F913714AD7F2Q36218312-628170BF-8F2A-42A3-8C25-73262409A6DAQ36379330-A5879394-2FFE-4786-B673-F6415CDB4201Q36607401-16C9FE1C-085B-42B7-87F4-A617737942D5Q36715742-5AF9CC57-2195-4E9B-AEFE-EAD3D994A2E3Q37412959-9F747B75-B82D-48A4-A638-4E2B9D59D938Q37845850-6598F1F2-57E6-4A5B-B6DC-1A53CCFD0BBEQ38665257-55F09B8A-A342-4F2F-8072-3B4F0BEA84E3Q39658100-5CE865AF-0FF3-4B17-A070-76F88ECBDFA1Q39730764-7BA934AF-3E8A-45EE-8002-CB56F21D500AQ39792528-3BD7A820-996C-4D0A-A7D3-E6664A2EB121Q41832949-3038F81B-9565-4C6C-8170-1C34B541A702Q41845485-9ED70C11-1CCF-462A-BF09-B074642D4912Q42432332-CB260EC0-A821-44B2-8F5A-C74EC2934F4CQ46634327-48591ED0-A857-49FA-AFEA-E4976ECCBC0D
P2860
Comparative in vitro activities of GAR-936 against aerobic and anaerobic animal and human bite wound pathogens.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
2000年论文
@zh
2000年论文
@zh-cn
name
Comparative in vitro activitie ...... nd human bite wound pathogens.
@en
Comparative in vitro activitie ...... nd human bite wound pathogens.
@nl
type
label
Comparative in vitro activitie ...... nd human bite wound pathogens.
@en
Comparative in vitro activitie ...... nd human bite wound pathogens.
@nl
prefLabel
Comparative in vitro activitie ...... nd human bite wound pathogens.
@en
Comparative in vitro activitie ...... nd human bite wound pathogens.
@nl
P2093
P2860
P1476
Comparative in vitro activitie ...... nd human bite wound pathogens.
@en
P2093
C V Merriam
D M Citron
E J Goldstein
P2860
P304
P356
10.1128/AAC.44.10.2747-2751.2000
P407
P577
2000-10-01T00:00:00Z